FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

J Berger

Research Profile

Chemicals & Drugs

Living Beings

Anatomy

Disorders

Concepts & Ideas

Kinetics

Co-author Network

Publications

TOP 3
J Berger; Michael Tanen; Alex Elbrecht; Anne Hermanowski-Vosatka; David E Moller; Samuel D Wright; Rolf Thieringer
Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity.
J Berger; Hansa V Patel; J Woods; N S Hayes; S A Parent; Joseph A Clemas; Mark D Leibowitz; Alex Elbrecht; Richard A Rachubinski; John P Capone; David E Moller
A PPARgamma mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus.
Alex Elbrecht; Y Chen; A Adams; J Berger; P Griffin; T Klatt; B Zhang; John G Menke; Gaochao Zhou; Roy G Smith; David E Moller
L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of J Berger (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2001: J Berger; Michael Tanen; Alex Elbrecht; Anne Hermanowski-Vosatka; David E Moller; Samuel D Wright; Rolf Thieringer
Peroxisome proliferator-activated receptor-gamma ligands inhibit adipocyte 11beta -hydroxysteroid dehydrogenase type 1 expression and activity.
The Journal of biological chemistry 2001;276(16):12629-35.
2000: J Berger; Hansa V Patel; J Woods; N S Hayes; S A Parent; Joseph A Clemas; Mark D Leibowitz; Alex Elbrecht; Richard A Rachubinski; John P Capone; David E Moller
A PPARgamma mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus.
Molecular and cellular endocrinology 2000;162(1-2):57-67.
1999: Alex Elbrecht; Y Chen; A Adams; J Berger; P Griffin; T Klatt; B Zhang; John G Menke; Gaochao Zhou; Roy G Smith; David E Moller
L-764406 is a partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding.
The Journal of biological chemistry 1999;274(12):7913-22.
1999: J Berger; Mark D Leibowitz; Thomas W Doebber; Alex Elbrecht; B Zhang; Gaochao Zhou; Chhabi Biswas; C A Cullinan; N S Hayes; Yueming Li; Michael Tanen; John Ventre; Margaret S Wu; G D Berger; Ralph T Mosley; R Marquis; C Santini; Soumya P Sahoo; Richard L Tolman; Roy G Smith; David E Moller
Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects.
The Journal of biological chemistry 1999;274(10):6718-25.
1996: B Zhang; J Berger; Gaochao Zhou; Alex Elbrecht; S Biswas; S White-Carrington; Deborah Szalkowski; David E Moller
Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma.
The Journal of biological chemistry 1996;271(50):31771-4.
1996: B Zhang; J Berger; E Hu; Deborah Szalkowski; S White-Carrington; Bruce M Spiegelman; David E Moller
Negative regulation of peroxisome proliferator-activated receptor-gamma gene expression contributes to the antiadipogenic effects of tumor necrosis factor-alpha.
Molecular endocrinology (Baltimore, Md.) 1996;10(11):1457-66.
1996: J Berger; P Bailey; C Biswas; C A Cullinan; Thomas W Doebber; N S Hayes; Richard Saperstein; Roy G Smith; M D Leibowitz
Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.
Endocrinology 1996;137(10):4189-95.
1996: Alex Elbrecht; Y Chen; C A Cullinan; N Hayes; M d Leibowitz; David E Moller; J Berger
Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2.
Biochemical and biophysical research communications 1996;224(2):431-7.
1996: J Berger; C Biswas; N Hayes; John Ventre; M Wu; Thomas W Doebber
An antidiabetic thiazolidinedione potentiates insulin stimulation of glycogen synthase in rat adipose tissues.
Endocrinology 1996;137(5):1984-90.
1995: Deborah Szalkowski; S White-Carrington; J Berger; B Zhang
Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells.
Endocrinology 1995;136(4):1474-81.
1994: J Berger; N Hayes; Deborah Szalkowski; B Zhang
PI 3-kinase activation is required for insulin stimulation of glucose transport into L6 myotubes.
Biochemical and biophysical research communications 1994;205(1):570-6.
1994: B Zhang; Deborah Szalkowski; Elva Diaz; N Hayes; R Smith; J Berger
Potentiation of insulin stimulation of phosphatidylinositol 3-kinase by thiazolidinedione-derived antidiabetic agents in Chinese hamster ovary cells expressing human insulin receptors and L6 myotubes.
The Journal of biological chemistry 1994;269(41):25735-41.
1993: N Hayes; C Biswas; H V Strout; J Berger
Activation by protein synthesis inhibitors of glucose transport into L6 muscle cells.
Biochemical and biophysical research communications 1993;190(3):881-7.
1990: H V Strout; Pasquale P Vicario; C Biswas; Richard Saperstein; Edward J Brady; P F Pilch; J Berger
Vanadate treatment of streptozotocin diabetic rats restores expression of the insulin-responsive glucose transporter in skeletal muscle.
Endocrinology 1990;126(5):2728-32.
1989: J Berger; C Biswas; Pasquale P Vicario; H V Strout; Richard Saperstein; P F Pilch
Decreased expression of the insulin-responsive glucose transporter in diabetes and fasting.
Nature 1989;340(6228):70-2.